B
Bettina Wahl
Researcher at Braunschweig University of Technology
Publications - 5
Citations - 385
Bettina Wahl is an academic researcher from Braunschweig University of Technology. The author has contributed to research in topics: Cytochrome b5 & Prodrug. The author has an hindex of 5, co-authored 5 publications receiving 357 citations.
Papers
More filters
Journal ArticleDOI
The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
Sanja Gruenewald,Bettina Wahl,Florian Bittner,Helen Hungeling,Stephanie Kanzow,Joscha Kotthaus,Ulrike Schwering,Ralf R. Mendel,Bernd Clement +8 more
TL;DR: The recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs, and the prodrug principle is not dependent on cytochrome P450 enzymes.
Journal ArticleDOI
Biochemical and spectroscopic characterization of the human mitochondrial amidoxime reducing components hmARC-1 and hmARC-2 suggests the existence of a new molybdenum enzyme family in eukaryotes.
Bettina Wahl,Debora Reichmann,Dimitri Niks,Nina Krompholz,Antje Havemeyer,Bernd Clement,Tania Messerschmidt,Martin Rothkegel,Harald Biester,Russ Hille,Ralf R. Mendel,Florian Bittner +11 more
TL;DR: The mARC-1/MOSC-1 and hmARC-2 genes were found to be monomeric in their active forms, which is in contrast to all other eukaryotic molybdenum enzymes that act as homo- or heterodimers.
Journal ArticleDOI
Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).
Juerke Kotthaus,Bettina Wahl,Antje Havemeyer,Joscha Kotthaus,Dennis Schade,Dieter Garbe-Schönberg,Ralf R. Mendel,Florian Bittner,Bernd Clement +8 more
TL;DR: It is shown for the first time that both human isoforms of the newly identified mARC (mitochondrial amidoxime reducing component) enhance the rate of reduction of NOHA, in the presence of NADH cytochrome b₅ reductase and cy tochrome b ₅, by more than 500-fold, providing the first hints that mARC might be involved in mitochondrial NOHA reduction and could be of physiological significance in affecting endogenous nitric oxide levels.
Biochemical and Spectroscopic Characterization of the Human Mitochondrial Amidoxime Reducing Components hmARC-1 and hmARC-2 Suggests the Existence of a New
Bettina Wahl,Debora Reichmann,Dimitri Niks,Nina Krompholz,Antje Havemeyer,Bernd Clement,Tania Messerschmidt,Martin Rothkegel,Harald Biester,Russ Hille,Ralf R. Mendel,Florian Bittner +11 more
TL;DR: Recombinant expression of hmARC-1 and hm ARC-2 proteins in Escherichia coli reveals that both proteins are monomeric in their active forms, which is in contrast to all other eukaryotic molybdenum enzymes that act as homo- or heterodimers.
Journal ArticleDOI
Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC.
Antje Havemeyer,Sanja Grünewald,Bettina Wahl,Florian Bittner,Ralf R. Mendel,Peter Erdelyi,János Fischer,Bernd Clement +7 more
TL;DR: It is demonstrated that N-hydroxy-valdecoxib is enzymatically reduced to its pharmacologically active metabolite valdecoxib, and is therefore a drug candidate in the treatment of diseases associated with rheumatic inflammation, pain, and fever.